{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:55:43Z","timestamp":1769604943887,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s00277-022-04852-5","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T04:26:06Z","timestamp":1654057566000},"page":"1677-1688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Outcome prediction of chronic myeloid leukemia (CML) in children"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-064X","authenticated-orcid":false,"given":"Wing-Yan","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3528","authenticated-orcid":false,"given":"Daniel Ka-Leung","family":"Cheuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8323-9671","authenticated-orcid":false,"given":"Frankie Wai-Tsoi","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Wing-Kwan","family":"Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka-Ho","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin Kar-Huen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chak-Ho","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-8985","authenticated-orcid":false,"given":"Godfrey Chi-Fung","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"5405","key":"4852_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/243290a0","volume":"243","author":"JD Rowley","year":"1973","unstructured":"Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243(5405):290\u2013293. https:\/\/doi.org\/10.1038\/243290a0","journal-title":"Nature"},{"issue":"1","key":"4852_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1542\/peds.2004-2473","volume":"116","author":"F Millot","year":"2005","unstructured":"Millot F, Traore P, Guilhot J, Nelken B, Leblanc T, Leverger G, Plantaz D, Bertrand Y, Bordigoni P, Guilhot F (2005) Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia. Pediatrics 116(1):140\u2013143. https:\/\/doi.org\/10.1542\/peds.2004-2473","journal-title":"Pediatrics"},{"issue":"8","key":"4852_CR3","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1182\/blood-2011-10-380774","volume":"119","author":"JR Andolina","year":"2012","unstructured":"Andolina JR, Neudorf SM, Corey SJ (2012) How I treat childhood CML. Blood 119(8):1821\u20131830. https:\/\/doi.org\/10.1182\/blood-2011-10-380774","journal-title":"Blood"},{"issue":"9","key":"4852_CR4","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","volume":"346","author":"DG Savage","year":"2002","unstructured":"Savage DG, Antman KH (2002) Imatinib mesylate--a new oral targeted therapy. N Engl J Med 346(9):683\u2013693. https:\/\/doi.org\/10.1056\/NEJMra013339","journal-title":"N Engl J Med"},{"issue":"4","key":"4852_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","volume":"120","author":"S Luatti","year":"2012","unstructured":"Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F et al (2012) Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 120(4):761\u2013767. https:\/\/doi.org\/10.1182\/blood-2011-10-384651","journal-title":"Blood"},{"issue":"26","key":"4852_CR6","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A, Muller MC, Hanfstein B, Haferlach C, Gohring G, Schlegelberger B, Jotterand M, Reiter A, Jung-Munkwitz S, Proetel U, Schwaab J, Hofmann WK, Schubert J, Einsele H, Ho AD, Falge C, Kanz L et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118(26):6760\u20136768. https:\/\/doi.org\/10.1182\/blood-2011-08-373902","journal-title":"Blood"},{"issue":"25","key":"4852_CR7","doi-asserted-by":"publisher","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","volume":"117","author":"G Marzocchi","year":"2011","unstructured":"Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F et al (2011) Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. Blood 117(25):6793\u20136800. https:\/\/doi.org\/10.1182\/blood-2011-01-328294","journal-title":"Blood"},{"issue":"18","key":"4852_CR8","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1002\/cncr.30767","volume":"123","author":"F Millot","year":"2017","unstructured":"Millot F, Dupraz C, Guilhot J, Suttorp M, Brizard F, Leblanc T, Gunes AM, Sedlacek P, De Bont E, Li CK, Kalwak K, Lausen B, Culic S, Dworzak M, Kaiserova E, De Moerloose B, Roula F, Biondi A, Baruchel A, Guilhot F (2017) Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. Cancer 123(18):3609\u20133616. https:\/\/doi.org\/10.1002\/cncr.30767","journal-title":"Cancer"},{"issue":"1","key":"4852_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G, Hoffmann VS, Castagnetti F, Hasford J, Hehlmann R, Simonsson B (2016) Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 30(1):48\u201356. https:\/\/doi.org\/10.1038\/leu.2015.261","journal-title":"Leukemia"},{"issue":"10","key":"4852_CR10","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.3324\/haematol.2017.170035","volume":"102","author":"F Millot","year":"2017","unstructured":"Millot F, Guilhot J, Suttorp M, Gunes AM, Sedlacek P, De Bont E, Li CK, Kalwak K, Lausen B, Culic S, Dworzak M, Kaiserova E, De Moerloose B, Roula F, Biondi A, Baruchel A (2017) Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica 102(10):1704\u20131708. https:\/\/doi.org\/10.3324\/haematol.2017.170035","journal-title":"Haematologica"},{"issue":"8","key":"4852_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/10245332.2017.1302179","volume":"22","author":"D Lekovic","year":"2017","unstructured":"Lekovic D, Gotic M, Milic N, Zivojinovic B, Jovanovic J, Colovic N, Milosevic V, Bogdanovic A (2017) Predictive parameters for imatinib failure in patients with chronic myeloid leukemia. Hematology 22(8):460\u2013466. https:\/\/doi.org\/10.1080\/10245332.2017.1302179","journal-title":"Hematology"},{"issue":"6","key":"4852_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u2013884. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"key":"4852_CR13","first-page":"5","volume":"12","author":"ST Leung","year":"1995","unstructured":"Leung ST, Tse LY, Wong GWK, Law WY, Huen KF, Yeung WKY, VTF Y, Lau JTF, Oppenheimer SJ, Leung NK (1995) Standards for the anthrometric assessment of nutritional status of Hong Kong children. The Hong Kong Journal of Paediatrics 12:5\u201315","journal-title":"The Hong Kong Journal of Paediatrics"},{"issue":"5","key":"4852_CR14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/j.1651-2227.1996.tb14101.x","volume":"85","author":"GW Wong","year":"1996","unstructured":"Wong GW, Leung SS, Law WY, Yeung VT, Lau JT, Yeung WK (1996) Secular trend in the sexual maturation of southern Chinese boys. Acta Paediatr 85(5):620\u2013621. https:\/\/doi.org\/10.1111\/j.1651-2227.1996.tb14101.x","journal-title":"Acta Paediatr"},{"key":"4852_CR15","unstructured":"Population by Year and Age (2016) https:\/\/itable.bycensus2016.gov.hk\/UI\/Report\/Report.aspx. Accessed 13 Feb 2021"},{"issue":"10","key":"4852_CR16","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/sj.bmt.1704255","volume":"32","author":"F Millot","year":"2003","unstructured":"Millot F, Esperou H, Bordigoni P, Dalle JH, Michallet M, Michel G, Bourhis JL, Kuenz M, Blaise D, Garban F, Plouvier E, Rome A, Guilhot J, Guilhot F (2003) Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 32(10):993\u2013999. https:\/\/doi.org\/10.1038\/sj.bmt.1704255","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"4852_CR17","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood-2003-09-3032","volume":"104","author":"MA Champagne","year":"2004","unstructured":"Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M, Children\u2019s Oncology Group phase s (2004) Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children\u2019s Oncology Group phase 1 study. Blood 104(9):2655\u20132660. https:\/\/doi.org\/10.1182\/blood-2003-09-3032","journal-title":"Blood"},{"issue":"3","key":"4852_CR18","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/bjh.13453","volume":"170","author":"F Giona","year":"2015","unstructured":"Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piciocchi A et al (2015) Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol 170(3):398\u2013407. https:\/\/doi.org\/10.1111\/bjh.13453","journal-title":"Br J Haematol"},{"issue":"6","key":"4852_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3324\/haematol.2009.016766","volume":"95","author":"W Deenik","year":"2010","unstructured":"Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk KM, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Lowenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ (2010) Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 95(6):914\u2013921. https:\/\/doi.org\/10.3324\/haematol.2009.016766","journal-title":"Haematologica"},{"issue":"20","key":"4852_CR20","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.2010.32.7114","volume":"29","author":"F Millot","year":"2011","unstructured":"Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y, Mazingue F, Lutz P, Verite C, Berthou C, Galambrun C, Bernard F, Yacouben K, Bordigoni P, Edan C, Reguerre Y, Couillault G, Mechinaud F, Cayuela JM, Guilhot F (2011) Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 29(20):2827\u20132832. https:\/\/doi.org\/10.1200\/JCO.2010.32.7114","journal-title":"J Clin Oncol"},{"issue":"13","key":"4852_CR21","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/JCO.2017.75.9597","volume":"36","author":"L Gore","year":"2018","unstructured":"Gore L, Kearns PR, de Martino ML, Lee DSCA, Bertrand Y, Hijiya N, Stork LC, Chung NG, Cardos RC, Saikia T, Fagioli F, Seo JJ, Landman-Parker J, Lancaster D, Place AE, Rabin KR, Sacchi M, Swanink R, Zwaan CM (2018) Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase: results from a phase II trial. J Clin Oncol 36(13):1330\u20131338. https:\/\/doi.org\/10.1200\/JCO.2017.75.9597","journal-title":"J Clin Oncol"},{"issue":"9","key":"4852_CR22","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s12098-015-2007-9","volume":"83","author":"RR Ganta","year":"2016","unstructured":"Ganta RR, Nasaka S, Gundeti S (2016) Impact of imatinib adherence on the cytogenetic response in pediatric chronic myeloid leukemia - chronic phase. Indian J Pediatr 83(9):1009\u20131012. https:\/\/doi.org\/10.1007\/s12098-015-2007-9","journal-title":"Indian J Pediatr"},{"issue":"22","key":"4852_CR23","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood.2018882233","volume":"133","author":"N Hijiya","year":"2019","unstructured":"Hijiya N, Suttorp M (2019) How I treat chronic myeloid leukemia in children and adolescents. Blood 133(22):2374\u20132384. https:\/\/doi.org\/10.1182\/blood.2018882233","journal-title":"Blood"},{"issue":"8","key":"4852_CR24","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/pbc.26028","volume":"63","author":"J Samis","year":"2016","unstructured":"Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N (2016) Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer 63(8):1332\u20131338. https:\/\/doi.org\/10.1002\/pbc.26028","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"4852_CR25","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/MCP.0b013e328338c486","volume":"16","author":"AG Brixey","year":"2010","unstructured":"Brixey AG, Light RW (2010) Pleural effusions due to dasatinib. Curr Opin Pulm Med 16(4):351\u2013356. https:\/\/doi.org\/10.1097\/MCP.0b013e328338c486","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"4852_CR26","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1097\/MPH.0000000000001619","volume":"42","author":"K Hickman","year":"2020","unstructured":"Hickman K, Diaz E, Graham R, Adams R, Ngwube A (2020) Dasatinib-induced chylothorax in chronic myelogenous leukemia in pediatric patient: report of a case and review of literature. J Pediatr Hematol Oncol 42(7):e665\u2013e667. https:\/\/doi.org\/10.1097\/MPH.0000000000001619","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"4852_CR27","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen J, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"11","key":"4852_CR28","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90(11):850\u2013858. https:\/\/doi.org\/10.1093\/jnci\/90.11.850","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4852_CR29","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F et al (1984) Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood 63(4):789\u2013799","journal-title":"Blood"},{"issue":"8","key":"4852_CR30","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00277-015-2367-2","volume":"94","author":"D Gurrea Salas","year":"2015","unstructured":"Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M (2015) Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol 94(8):1363\u20131371. https:\/\/doi.org\/10.1007\/s00277-015-2367-2","journal-title":"Ann Hematol"},{"issue":"21","key":"4852_CR31","doi-asserted-by":"publisher","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N et al (2011) Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood 117(21):5591\u20135599. https:\/\/doi.org\/10.1182\/blood-2010-12-324228","journal-title":"Blood"},{"issue":"6","key":"4852_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen J, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Stromberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, Machova Polakova K, Muller MC, Mustjoki S et al (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19(6):747\u2013757. https:\/\/doi.org\/10.1016\/S1470-2045(18)30192-X","journal-title":"Lancet Oncol"},{"key":"4852_CR33","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejca.2017.02.028","volume":"77","author":"L Campiotti","year":"2017","unstructured":"Campiotti L, Suter MB, Guasti L, Piazza R, Gambacorti-Passerini C, Grandi AM, Squizzato A (2017) Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer 77:48\u201356. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.028","journal-title":"Eur J Cancer"},{"issue":"7","key":"4852_CR34","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41375-018-0179-9","volume":"32","author":"M Suttorp","year":"2018","unstructured":"Suttorp M, Schulze P, Glauche I, Gohring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont E, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C et al (2018) Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. Leukemia 32(7):1657\u20131669. https:\/\/doi.org\/10.1038\/s41375-018-0179-9","journal-title":"Leukemia"},{"issue":"2","key":"4852_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/bjh.13103","volume":"168","author":"F Giona","year":"2015","unstructured":"Giona F, Saglio G, Moleti ML, Piciocchi A, Rea M, Nanni M, Marzella D, Testi AM, Mariani S, Laurino M, Diverio D, Gottardi E, Foa R (2015) Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. Br J Haematol 168(2):305\u2013308. https:\/\/doi.org\/10.1111\/bjh.13103","journal-title":"Br J Haematol"},{"key":"4852_CR36","unstructured":"Children\u2019s Oncology Group NCIN stopping tyrosine kinase inhibitors in affecting treatment-free remission in patients with chronic phase chronic myeloid leukemia. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03817398. Accessed 25 Feb 2021"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04852-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04852-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T13:08:48Z","timestamp":1657717728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04852-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["4852"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04852-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,1]]},"assertion":[{"value":"17 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research Ethics Committees of all involved hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}